Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neural Transm (Vienna) ; 114(8): 959-68, 2007.
Article in English | MEDLINE | ID: mdl-17520319

ABSTRACT

The majority of recreational Ecstasy/MDMA users (90-98%) also take cannabis. This co-drug usage is often viewed as a methodological confound, which needs to be removed statistically. Here we take a rather different approach, and debate the potential complexities of their psychobiological interactions. The ring-substituted amphetamine derivate MDMA (3,4-methylendioxymethamphetmaine, or 'Ecstasy') is a powerful CNS stimulant, whereas cannabis is a relaxant. Their co-usage may reflect opposing effects in three psychobiological areas: arousal, body temperature, and oxidative stress. Firstly MDMA is alerting whereas cannabis is sedating. Secondly MDMA is hyperthermic whereas cannabis is hypothermic. Thirdly MDMA increases oxidative stress whereas cannabinoids are antioxidant. Hence cannabis may modulate the acute and sub-acute reactions to MDMA, reduce the acute hyperthermia induced by MDMA, and ameliorate the oxidative stress caused by MDMA. The limited empirical evidence on each topic will be critically examined. In terms of chronic effects each drug is functionally damaging, so that polydrug users generally display cumulative neurobiological impairments. However in certain aspects their neuropsychobiological effects may interactive rather than additive. In particular, the combined use of cannabis and MDMA may have rather different neuropsychobiological implications, than their separate usage. In order to investigate these potential complexities, future research will need better empirical data on the exact patterns of co-drug usage.


Subject(s)
Cannabis/adverse effects , Hallucinogens/adverse effects , Marijuana Abuse/physiopathology , N-Methyl-3,4-methylenedioxyamphetamine/adverse effects , Neurocognitive Disorders/chemically induced , Animals , Cytoprotection/drug effects , Drug Interactions , Fever/chemically induced , Fever/physiopathology , Humans , Marijuana Abuse/psychology , Neurocognitive Disorders/physiopathology , Oxidative Stress/drug effects , Risk Factors
2.
Hum Psychopharmacol ; 20(4): 249-61, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15816011

ABSTRACT

Cannabis is one of the most common 'co-drugs' for ecstasy users. The aim of the present study was to explore self-reported psychobiological problems in ecstasy polydrug users in relation to their pattern of cannabis use. Two hundred and eighty ecstasy polydrug users were allocated into five cannabis groups according to the frequency of their cannabis use. The control group comprised 121 alcohol-tobacco users. There were no significant group differences with regard to age, diagnosed family psychiatric history and level of self-rated stress experienced during 6 months prior to the study. The present study produced three main findings: (a) Ecstasy users with no concomitant use of cannabis displayed more self-rated aggression and somatic symptoms compared with ecstasy users who were smoking cannabis on a monthly or weekly basis. (b) Ecstasy users who reported heavy cannabis use in the past displayed higher paranoid symptoms compared with ecstasy weekly and daily cannabis users. (c) Former heavy cannabis users were the most likely to complain of a variety of ecstasy related long-term problems. In conclusion, moderate cannabis use may help to ameliorate or mask MDMA-induced aggressivity and somatic symptoms. However, this study confirms that heavy cannabis and ecstasy use is associated with several psychobiological problems, which may emerge after a period of abstinence from both drugs.


Subject(s)
Aggression/drug effects , Marijuana Abuse/psychology , N-Methyl-3,4-methylenedioxyamphetamine , Substance-Related Disorders/psychology , Adult , Alcohol Drinking/psychology , Cognition Disorders/chemically induced , Cognition Disorders/psychology , Drug Interactions , Family , Female , Humans , Likelihood Functions , Male , Marijuana Abuse/complications , Psychiatric Status Rating Scales , Smoking/psychology , Stress, Psychological/complications , Stress, Psychological/psychology , Substance-Related Disorders/complications , Surveys and Questionnaires
3.
Psychopharmacology (Berl) ; 159(1): 77-82, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11797073

ABSTRACT

RATIONALE: Recreational drug use is increasingly widespread amongst young people, but there are concerns that psychoactive drugs may be associated with psychiatric symptoms or psychobiological problems. OBJECTIVES: To assess the psychiatric health status of a large, non-clinical sample of young adults from Italy and the UK, and relate it to their use of ecstasy/MDMA and other recreational drugs. METHODS: The UEL Recreational Drug Use Questionnaire was completed by 768 young people (mean age 21.7 years) from four European cities. The subjects comprised 150 non-drug users, 185 alcohol/tobacco users, 97 cannabis and alcohol/tobacco users, 102 illicit polydrug but not ecstasy users, 115 light (<20 times) ecstasy polydrug users, and 119 heavy (>20 times) ecstasy polydrug users. The unpaid volunteers completed the SCL-90 self-rating inventory for psychiatric symptoms when off drug, with 30 additional questions covering positive moods and life experiences. RESULTS: Heavy ecstasy polydrug users reported significantly higher scores than non-drug users on several SCL-90 factors, including phobic anxiety, obsessive-compulsive behaviour, anxiety, psychoticism, somatisation, and significantly higher rates of 'loss of sex interest or pleasure'. Self-rated symptom scores increased in line with greater drug use, so that polydrug users who had never taken ecstasy also reported a variety of psychobiological impairments. In contrast, positive moods and life experiences were broadly similar across subgroups. CONCLUSIONS: The recreational use of ecstasy/MDMA is associated with a range of psychiatric symptoms and psychobiological problems. However, these problems are not specific to ecstasy users but are also evident in other recreational polydrug users.


Subject(s)
Illicit Drugs/adverse effects , Mental Disorders/chemically induced , Mental Disorders/psychology , N-Methyl-3,4-methylenedioxyamphetamine/adverse effects , Serotonin Agents/adverse effects , Substance-Related Disorders/psychology , Adolescent , Adult , Analysis of Variance , Female , Humans , Italy/epidemiology , Male , Mental Disorders/epidemiology , Psychiatric Status Rating Scales/statistics & numerical data , Substance-Related Disorders/epidemiology , United Kingdom/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...